Back Login to subscribe 🔔 Set Alert

APRE Aprea Therapeutics, Inc. Common stock

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors	53.97%
	Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6	94.33%
	Earnings Scheduled For May 13, 2026	92.87%
	Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate	65.31%
	This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday	92.88%
	Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5	62.26%
	12 Health Care Stocks Moving In Monday's Pre-Market Session	95.56%